SCHEMBL3909627

SCHEMBL3909627

Fc1c(OCc2ccccc2)ccc2[nH]ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.43
DRD4 P21917 2/20 0.43
DRD3 P35462 2/20 0.43
KDM1A O60341 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
NSD2 O96028 1/20 0.41
ABL1 P00519 1/20 0.41
PPARG P37231 1/20 0.41
RIN1 Q13671 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
MAPT P10636 4/20 0.40
HTR1A P08908 2/20 0.40
MAPK1 P28482 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
KDM4E B2RXH2 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1994140 0.82 DRD2 (0.43) DRD2DRD4DRD3L3MBTL1NSD2
SCHEMBL30390986 0.82 L3MBTL1 (0.56) DRD2DRD4DRD3L3MBTL1NSD2
SCHEMBL8546338 0.82 MAPK14 (0.43) DRD2DRD4DRD3L3MBTL1NSD2
SCHEMBL746079 0.80 DRD4 (0.63) DRD2DRD4DRD3L3MBTL1MAPT
SCHEMBL29415608 0.80 DRD4 (0.63) DRD2DRD4DRD3L3MBTL1MAPT
SCHEMBL3897534 0.79 POLB (0.43) DRD2DRD4DRD3L3MBTL1MAPT
SCHEMBL1163314 0.79 KDM1A (0.46) DRD2DRD4DRD3KDM1AL3MBTL1
SCHEMBL18683086 0.78 NPC1 (0.62) DRD2DRD4DRD3L3MBTL1NSD2
SCHEMBL12559151 0.78 KDM1A (0.45) DRD2DRD4DRD3KDM1AL3MBTL1
SCHEMBL1401701 0.77 IRAK1 (0.54) KDM1AABL1CTSVCTSLTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 US disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 EP disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE S1PR3, S1PR2, S1PR1 DRD2 538/4885DRD4 1765/4885DRD3 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.